Protocol M16-000: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006

Project: Research project

Project Details

StatusActive
Effective start/end date7/1/193/4/23

Funding

  • AbbVie Inc. (Protocol M16-000)